This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Tecentriq
  • /
  • A Study of Atezolizumab in Participants With Progr...
Clinical trial

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (BIRCH)

Read time: 3 mins
Last updated:1st Jan 2014
Identifier: NCT02031458

This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Study Type: Interventional
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Enrollment: 659
Study Start Date: January 2014
Estimated Study Completion Date: August 2017
Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)

- Experimental:

Category Value
Date last updated at source 2017-05-15
Study type(s) Interventional
Expected enrolment 659
Study start date 2014-01-01
Estimated primary completion date 2016-11-01

View full details